Skip to main content

Briacell Therapeutics Corp(BCT-T)
TSX

Today's Change
Real-Time Last Update
Day Low5.05
Day High5.54
Open:5.54
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Briacell Therapeutics Corp

Select a category then submit the form to load news
GlobeNewswire
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
GlobeNewswire
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
GlobeNewswire
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
GlobeNewswire
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Newsfile
Upcoming Meeting Dates - January 19, 2026
The Globe and Mail
The Globe’s stars and dogs for the week
For Stars and Dogs column in Globe Investor/ROB only.
GlobeNewswire
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
BayStreet.ca
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush
GlobeNewswire
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
GlobeNewswire
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
Newswire.ca
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
GlobeNewswire
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
GlobeNewswire
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
GlobeNewswire
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
GlobeNewswire
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
GlobeNewswire
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
GlobeNewswire
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
GlobeNewswire
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
GlobeNewswire
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
GlobeNewswire
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
GlobeNewswire
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
GlobeNewswire
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
BayStreet.ca
Cancer Treatment Revolution Drives $903B Market as New Therapies Gain Momentum
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
GlobeNewswire
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
GlobeNewswire
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
GlobeNewswire
BriaCell Announces Proposed Effective Date of Share Consolidation

Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.